Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seoul National University Bundang Hospital
Patients who were diagnosed with left ventricular hypertrophy (LVH) by ECG at the start of the study are followed up at 3-month intervals for 1 year.
Increase Fimasartan if blood pressure is not controlled.
Age
20–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who have been treated or not treated with hypertension from 20 to 80 years of age
Patients with electrocardiographic left ventricular hypertrophy (In this study, we define left ventricular hypertrophy if one of the following two criteria is met)
1. RaVL+SV3 \> 20mm(M). 16mm(F)
2. SV1+RV5 or RV6 \> 35mm.
Patients who are taking or expecting Fimasartan
You may not be if
Patients with unstable angina or myocardial infarction within 3 months
Patients with clinically significant severe valve disease, congenital heart disease, peripheral vascular disease, cerebrovascular disease
Clinically significant severe congestive heart failure patients
Patients with renal dialysis
Clinically significant renal disease patients
Patients with clinically significant hepatic impairment
Patients with a history of alcohol or substance abuse
Patients with hypersensitivity to angiotensin-receptor blocker
Patients needing angiotensin-receptor blocker drugs other than fimasartan
For women, pregnancy, Patients who are breastfeeding or planning to become pregnant
A person who is determined to be inappropriate by the Investigator
Patients participating in other clinical trials
Clareo Health | Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG
